In vivo, the loss of NLRP3 inflammasome or caspase-1 activity has been found to inhibit the priming and activation of CTLs, thereby significantly blocking the cytotoxic effects of CTLs against tumour cells in mouse models [50,59]. Here, NLRP3 is linked to neoplasm.